WO2002062384A3 - Reduced fluence rate pdt - Google Patents

Reduced fluence rate pdt Download PDF

Info

Publication number
WO2002062384A3
WO2002062384A3 PCT/CA2002/000135 CA0200135W WO02062384A3 WO 2002062384 A3 WO2002062384 A3 WO 2002062384A3 CA 0200135 W CA0200135 W CA 0200135W WO 02062384 A3 WO02062384 A3 WO 02062384A3
Authority
WO
WIPO (PCT)
Prior art keywords
fluence rate
reduced fluence
pdt
rate pdt
reduced
Prior art date
Application number
PCT/CA2002/000135
Other languages
French (fr)
Other versions
WO2002062384A2 (en
Inventor
H Andrew Strong
Original Assignee
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Tech Inc filed Critical Quadra Logic Tech Inc
Priority to EP02711694A priority Critical patent/EP1357946B1/en
Priority to DE60225783T priority patent/DE60225783T2/en
Priority to CA2437557A priority patent/CA2437557C/en
Priority to ES02711694T priority patent/ES2304429T3/en
Publication of WO2002062384A2 publication Critical patent/WO2002062384A2/en
Publication of WO2002062384A3 publication Critical patent/WO2002062384A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

The invention relates to the use of reduced fluence rate PDT to treat neovasculature, particularly choroidal neovasculature (CNV). Reduced fluence rate PDT decreases the likelihood of molecular oxygen being the limiting factor in the photodynamic reaction so that the concentration of either photons (light intensity) or photosensitizer in the target tissue controls the photodynamic reaction.
PCT/CA2002/000135 2001-02-06 2002-02-06 Reduced fluence rate pdt WO2002062384A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02711694A EP1357946B1 (en) 2001-02-06 2002-02-06 Photodynamic therapy with reduced fluence rate
DE60225783T DE60225783T2 (en) 2001-02-06 2002-02-06 PHOTODYNAMIC THERAPY WITH REDUCED IRRADIATION THICKNESS
CA2437557A CA2437557C (en) 2001-02-06 2002-02-06 Reduced total fluence photodynamic therapy of choroidal neovasculature in amd
ES02711694T ES2304429T3 (en) 2001-02-06 2002-02-06 PHOTODYNAMIC THERAPY WITH REDUCED FLUENCE INDEX.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26696001P 2001-02-06 2001-02-06
US60/266,960 2001-02-06

Publications (2)

Publication Number Publication Date
WO2002062384A2 WO2002062384A2 (en) 2002-08-15
WO2002062384A3 true WO2002062384A3 (en) 2003-05-15

Family

ID=23016703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000135 WO2002062384A2 (en) 2001-02-06 2002-02-06 Reduced fluence rate pdt

Country Status (8)

Country Link
US (2) US6800086B2 (en)
EP (1) EP1357946B1 (en)
AT (1) ATE390147T1 (en)
CA (1) CA2437557C (en)
DE (1) DE60225783T2 (en)
ES (1) ES2304429T3 (en)
PT (1) PT1357946E (en)
WO (1) WO2002062384A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60143514D1 (en) * 2000-02-11 2011-01-05 Gen Hospital Corp PHOTOCHEMICAL TISSUE CONNECTION
US7073510B2 (en) * 2000-02-11 2006-07-11 The General Hospital Corporation Photochemical tissue bonding
EP1357945A2 (en) 2001-02-06 2003-11-05 QLT Inc. Method to prevent vision loss
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
CA2437557C (en) * 2001-02-06 2012-07-24 Qlt Inc. Reduced total fluence photodynamic therapy of choroidal neovasculature in amd
US7303578B2 (en) 2001-11-01 2007-12-04 Photothera, Inc. Device and method for providing phototherapy to the brain
US20050159793A1 (en) * 2002-07-02 2005-07-21 Jackson Streeter Methods for treating macular degeneration
FR2842413B1 (en) * 2002-07-18 2005-06-03 Univ Lille Sciences Tech APPARATUS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)
US20040110731A1 (en) * 2002-12-04 2004-06-10 Chan Agnes H. Photodynamic therapy for the treatment of non-melanoma skin cancer
US7354432B2 (en) * 2003-01-17 2008-04-08 Mcw Research Foundation, Inc. Red to near-infrared photobiomodulation treatment of the visual system in visual system disease or injury
US20050059731A1 (en) * 2003-09-16 2005-03-17 Ceramoptec Industries, Inc. Erythrosin-based antimicrobial photodynamic therapy compound and its use
FR2864903B1 (en) * 2004-01-14 2006-09-15 Optical System Res For Industr APPARATUS FOR THE TREATMENT, IN PARTICULAR BY LASER, OF A CANCER OR PRECANCEROUS CONDITION
WO2006036176A1 (en) * 2004-09-24 2006-04-06 Light Sciences Corporation Extended treatment of tumors through vessel occlusion with light activated drugs
WO2006041744A2 (en) * 2004-10-05 2006-04-20 Light Sciences Corporation Low energy pdt for ocular disease
WO2006065727A1 (en) * 2004-12-15 2006-06-22 Light Sciences Corporation Enhanced occlusive effect photodynamic therapy
US20060134004A1 (en) * 2004-12-21 2006-06-22 The University Of Utah Methods and apparatus for detection of carotenoids in macular tissue
US20060244913A1 (en) 2004-12-21 2006-11-02 Werner Gellermann Imaging of macular pigment distributions
JP2008530235A (en) * 2005-02-17 2008-08-07 ライト サイエンシーズ オンコロジー， インコーポレイテッド Photoreactive system and prophylactic treatment of atherosclerosis
UA80467C2 (en) * 2005-08-31 2007-09-25 Leonid Andriiovych Lynnyk Method and device for treating macular dystrophy
US20070123844A1 (en) * 2005-10-19 2007-05-31 Shelly Henry Method for treating ocular disorders
HRP20060149B1 (en) * 2006-04-19 2008-11-30 Institut "Ruđer Bošković" Intelligent sequential illuminator photodynamic therapy
JP5346587B2 (en) * 2006-11-30 2013-11-20 学校法人慶應義塾 Abnormal electrical conduction blocking device using photodynamic therapy (PDT)
US8785491B2 (en) * 2008-06-19 2014-07-22 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceutical compositions and methods for treating age-related macular degeneration with melatonin analogues
US9226917B2 (en) 2008-12-16 2016-01-05 Valeant Pharmaceuticals International, Inc. Photodynamic therapy for conditions of the eye
EP3618734B1 (en) 2017-05-03 2021-06-30 Medtronic Vascular, Inc. Tissue-removing catheter
US11690645B2 (en) 2017-05-03 2023-07-04 Medtronic Vascular, Inc. Tissue-removing catheter
US11638833B2 (en) 2017-08-02 2023-05-02 Multi Radiance Medical Reducing light polution in photobiomodulation therapy of a patients eye
CA3071842C (en) 2017-08-02 2022-07-19 Multi Radiance Medical System and method for directing light into a patient's eye
US11819236B2 (en) 2019-05-17 2023-11-21 Medtronic Vascular, Inc. Tissue-removing catheter

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024930A1 (en) * 1994-03-14 1995-09-21 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
WO2001035996A2 (en) * 1999-11-17 2001-05-25 Qlt Inc. Use of pdt to inhibit intimal hyperplasia
US20010023247A1 (en) * 1994-03-14 2001-09-20 Miller Joan W. Use of green porphyrins to treat neovasculature in the eye
WO2002062386A2 (en) * 2001-02-06 2002-08-15 Qlt Inc. Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
ATE244244T1 (en) 1996-10-01 2003-07-15 Wyeth Lederle Japan Ltd IMINOCHLORINASPARAGIC ACID DERIVATIVES
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US7125542B2 (en) 2000-02-10 2006-10-24 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US6524330B1 (en) * 2000-10-27 2003-02-25 Bahram Khoobehi Method of ocular treatment
CA2437557C (en) * 2001-02-06 2012-07-24 Qlt Inc. Reduced total fluence photodynamic therapy of choroidal neovasculature in amd

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024930A1 (en) * 1994-03-14 1995-09-21 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
US20010023247A1 (en) * 1994-03-14 2001-09-20 Miller Joan W. Use of green porphyrins to treat neovasculature in the eye
WO2001035996A2 (en) * 1999-11-17 2001-05-25 Qlt Inc. Use of pdt to inhibit intimal hyperplasia
WO2002062386A2 (en) * 2001-02-06 2002-08-15 Qlt Inc. Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FOSTER, THOMAS H. ET AL: "Analysis of photochemical oxygen consumption effects in photodynamic therapy", PROCEEDINGS OF SPIE-THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING (1992), 1645(PROC. OPT. METHODS TUMOR TREAT. DETECT.: MECH. TECH. PHOTODYN. THER., 1992), 104-14, XP008013788 *
HENDERSON B W ET AL: "Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate.", CANCER RESEARCH. UNITED STATES 1 FEB 2000, vol. 60, no. 3, 1 February 2000 (2000-02-01), pages 525 - 529, XP002231035, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
CA2437557A1 (en) 2002-08-15
DE60225783D1 (en) 2008-05-08
PT1357946E (en) 2008-06-27
ATE390147T1 (en) 2008-04-15
US20050070518A1 (en) 2005-03-31
ES2304429T3 (en) 2008-10-16
DE60225783T2 (en) 2009-04-09
EP1357946B1 (en) 2008-03-26
EP1357946A2 (en) 2003-11-05
US6800086B2 (en) 2004-10-05
WO2002062384A2 (en) 2002-08-15
CA2437557C (en) 2012-07-24
US20020173832A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
WO2002062384A3 (en) Reduced fluence rate pdt
WO2002096366A3 (en) Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
WO2003003975A3 (en) Detection and therapy of vulnerable plaque with photodynamic compounds
ATE526989T1 (en) PHOTODYNAMIC THERAPY WITH CHEMOLUMINESCENCE AND LIGAND-PHOTOSENSITIZER CONJUGATE
RS35404A (en) Methods for treating ocular neovascular diseases
IT1333697B (en)
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
AU2003248747A1 (en) Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
DK0906758T3 (en) Zinc phthalocyanines and similar conjugates, their production and use in photodynamic therapy and as diagnostic agents
HUP0000576A2 (en) Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts
MX2011006376A (en) Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature.
WO2002062385A3 (en) Method to prevent vision loss
ATE306281T1 (en) ANTIVIRAL AGENT IN COMBINATION WITH RADIATION THERAPY FOR USE IN THE TREATMENT OF CANCER
WO2001074389A3 (en) Improved treatment of neovascularization
WO2002096365A3 (en) Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy
WO2003008430A3 (en) Porphyrin derivatives for photodynamic therapy
WO2003028629A3 (en) Chlorin photosensitizing agents for use in photodynamic therapy
MXPA04007443A (en) Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases.
WO2005048944A3 (en) Activatable photodynamic therapy agents
WO2003028628A3 (en) Photosensitizing carbamate derivatives
WO2004034889A3 (en) Photodynamic therapy for ocular neovascularization
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
EP1550449A4 (en) Antitumor agents with the use of hsv
GB2360785A8 (en) 2-Aza-21-carbaporphyrins (N-confused porphyrins) with (hydroxy/alkoxy)phenyl meso-substituents for photodynamic therapy & the treatment of tumours
WO2003018006A1 (en) Porphyrin-zinc oxide complex and use of the same as photosensitive medicament which exitates photodynamic action by radiation and the use thereof in targeted therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2437557

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002711694

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002711694

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWG Wipo information: grant in national office

Ref document number: 2002711694

Country of ref document: EP